JP2019517485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517485A5 JP2019517485A5 JP2018562232A JP2018562232A JP2019517485A5 JP 2019517485 A5 JP2019517485 A5 JP 2019517485A5 JP 2018562232 A JP2018562232 A JP 2018562232A JP 2018562232 A JP2018562232 A JP 2018562232A JP 2019517485 A5 JP2019517485 A5 JP 2019517485A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- fluoro
- weeks
- administered
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342822P | 2016-05-27 | 2016-05-27 | |
| US62/342,822 | 2016-05-27 | ||
| PCT/US2017/034855 WO2017205843A1 (en) | 2016-05-27 | 2017-05-26 | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517485A JP2019517485A (ja) | 2019-06-24 |
| JP2019517485A5 true JP2019517485A5 (enExample) | 2020-07-02 |
Family
ID=60412660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562232A Pending JP2019517485A (ja) | 2016-05-27 | 2017-05-26 | Ｂ細胞増殖性障害を治療するための抗ｃｄ２０抗体、ｐ１３キナーゼ−デルタ選択的阻害剤およびｂｔｋ阻害剤の組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10966977B2 (enExample) |
| EP (1) | EP3463318A4 (enExample) |
| JP (1) | JP2019517485A (enExample) |
| KR (1) | KR20190015351A (enExample) |
| CN (1) | CN109640964A (enExample) |
| AU (1) | AU2017268839A1 (enExample) |
| BR (1) | BR112018074238A2 (enExample) |
| CA (1) | CA3024123A1 (enExample) |
| CL (1) | CL2018003349A1 (enExample) |
| EA (1) | EA201892284A1 (enExample) |
| IL (1) | IL263239A (enExample) |
| MX (1) | MX2018014577A (enExample) |
| SG (1) | SG11201810333UA (enExample) |
| WO (1) | WO2017205843A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3892302T1 (sl) | 2015-04-06 | 2023-11-30 | Janssen Pharmaceutica Nv | Sestavki, ki vsebujejo ibrutinib |
| WO2019112381A1 (ko) * | 2017-12-08 | 2019-06-13 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 |
| KR20250134703A (ko) | 2018-05-11 | 2025-09-11 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법 |
| KR102844084B1 (ko) * | 2018-06-15 | 2025-08-07 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| WO2021009509A1 (en) * | 2019-07-15 | 2021-01-21 | Johnson Matthey Public Limited Company | Amorphous umbralisib monotosylate |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| US20240197778A1 (en) * | 2021-04-08 | 2024-06-20 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a her2 targeted antibody |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| US7663057B2 (en) | 2004-02-19 | 2010-02-16 | Nanosolar, Inc. | Solution-based fabrication of photovoltaic cell |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| US8543180B2 (en) | 2006-05-03 | 2013-09-24 | Covidien Lp | Method and apparatus for total hemoglobin measurement |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| PT2496567T (pt) | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| KR101988079B1 (ko) | 2012-07-04 | 2019-06-11 | 리젠 파마슈티컬스 소시에떼 아노님 | 선택적 pi3k 델타 억제제 |
| US9694071B2 (en) * | 2012-11-02 | 2017-07-04 | Tg Therapeutics, Inc. | Combination of anti-CD20 antibody and PI3 kinase selective inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| CA2949932C (en) | 2014-05-27 | 2021-08-10 | Rhizen Pharmaceuticals Sa | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
| JP2017523207A (ja) | 2014-08-08 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
-
2017
- 2017-05-26 MX MX2018014577A patent/MX2018014577A/es unknown
- 2017-05-26 WO PCT/US2017/034855 patent/WO2017205843A1/en not_active Ceased
- 2017-05-26 CA CA3024123A patent/CA3024123A1/en not_active Abandoned
- 2017-05-26 BR BR112018074238-4A patent/BR112018074238A2/pt not_active Application Discontinuation
- 2017-05-26 CN CN201780032933.0A patent/CN109640964A/zh active Pending
- 2017-05-26 EP EP17803731.3A patent/EP3463318A4/en not_active Withdrawn
- 2017-05-26 US US16/304,590 patent/US10966977B2/en not_active Expired - Fee Related
- 2017-05-26 AU AU2017268839A patent/AU2017268839A1/en not_active Abandoned
- 2017-05-26 JP JP2018562232A patent/JP2019517485A/ja active Pending
- 2017-05-26 KR KR1020187037436A patent/KR20190015351A/ko not_active Ceased
- 2017-05-26 SG SG11201810333UA patent/SG11201810333UA/en unknown
- 2017-05-26 EA EA201892284A patent/EA201892284A1/ru unknown
-
2018
- 2018-11-22 IL IL263239A patent/IL263239A/en unknown
- 2018-11-23 CL CL2018003349A patent/CL2018003349A1/es unknown
-
2021
- 2021-02-12 US US17/175,184 patent/US20210169878A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517485A5 (enExample) | ||
| US20240009196A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2019506403A5 (enExample) | ||
| JP2018524347A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| US12194095B2 (en) | Combinations and uses thereof | |
| JP2017506227A5 (enExample) | ||
| JP2017528462A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2019526595A5 (enExample) | ||
| JP2022137089A (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| JP2010512407A5 (enExample) | ||
| CN103732252B (zh) | 使用抗cd‑19抗体和氮芥的联合治疗 | |
| JP2020523384A5 (enExample) | ||
| JP2018524361A5 (enExample) | ||
| JP2015516980A5 (enExample) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| US20110129467A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| HK40120537A (zh) | 抗肿瘤组合物 | |
| HK40058495B (zh) | 抗肿瘤组合物 | |
| Bofill et al. | American Society of Hematology (ASH)-56Th Annual Meeting and Exposition-San Francisco, California, USA, December 6-9, 2014 |